Warsaw, Poland — ObNowa Pharma today announced its launch as a global pharmaceutical development company focused on medical aesthetics, headquartered in Poland — developing science-driven treatments across hair growth and neurotoxin-based aesthetics.
ObNowa's portfolio brings together two scientific lineages. The neurotoxin programs build on science originating from Object Pharma and are developed to global standards, while ObNowa's licensed rights to the hair-growth programs originating from Aneira Pharma support a focused European development and commercialization strategy.
ObNowa Pharma is headquartered in Poland, positioning the company within the European Union's regulatory and scientific framework. Its development philosophy is evidence-led: programs advance through disciplined preclinical and clinical pathways aligned with global regulatory standards, including European Medicines Agency requirements.
"Medical aesthetics deserves the same scientific rigour as any other field of medicine," the company stated. "ObNowa was founded to bring pharmaceutical discipline — scientific integrity, clinical evidence and rigorous development standards — to a category defined too often by marketing rather than data."
All ObNowa Pharma product candidates are investigational and have not been approved by the European Medicines Agency or any other regulatory authority. The company is actively engaging with licensing, clinical development, regulatory, manufacturing and commercial partners.
Development status — all programs presented are currently in research and development. Potential indications and applications reflect development objectives and do not represent established efficacy, safety or regulatory approval.